联合检测血清miR-125b和AFP对原发性肝细胞癌的诊断价值 |
| |
引用本文: | 左铎,罗艺,郭华,张宁. 联合检测血清miR-125b和AFP对原发性肝细胞癌的诊断价值[J]. 中国肿瘤临床, 2014, 41(10): 662-666. DOI: 10.3969/j.issn.1000-8179.20140337 |
| |
作者姓名: | 左铎 罗艺 郭华 张宁 |
| |
作者单位: | ①.天津医科大学肿瘤医院检验科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,国家“863”计划临床研究实验室(天津市 300060) |
| |
基金项目: | 国家重大科学研究计划973项目2011CB933100国家高技术研究发展计划863项目2011AA02A111天津医科大学肿瘤医院院级课题Y1302 |
| |
摘 要: | 目的 探讨血清中miR-125b作为原发性肝细胞癌(hepatocellular carcinoma,HCC)的血清标志物的可能性和联合检测miR-125b和AFP对HCC的诊断价值。 方法 通过实时荧光定量PCR(quantitative real-time polymerase chain reaction,RT-qPCR)检测65例HCC患者和30例健康对照组的血清miR-125b表达量,分析其对HCC的诊断价值,以及与HCC临床病理资料参数间的关系。 结果 HCC患者组血清miR-125b表达与对照组相比较低,且两者的差异有统计学意义(P < 0.05)。miR-125b的表达与患者性别、年龄、乙肝表面抗原阳性、AFP、ALT和α-GGT的表达水平无关(P > 0.05)。miR-125b的表达与患者肝硬化、肿瘤大小和TNM分期有关,且差异有统计学意义(P < 0.05)。单独检测miR-125b的ROC曲线下的AUC为0.917(95%CI:0.851~0.960,P < 0.001),灵敏性为85.9%,特异性为93.5%,联合miR-125b和AFP检测的ROC曲线下的AUC为0.951(95%CI:0.894~0.982,P < 0.001),灵敏性为92.9%,特异性为93.5%,检测AFP < 20 μg/L的HCC患者血清miR-125b的ROC曲线下的AUC为0.889(95%CI:0.776~0.957,P < 0.001),灵敏性为84.0%,特异性为87.1%。 结论 联合检测血清miR-125b和AFP对早期诊断原发性HCC具有重要的临床价值。
|
关 键 词: | 原发性 肝细胞癌 微小RNA 甲胎蛋白 诊断 实时荧光定量PCR |
收稿时间: | 2014-01-20 |
The diagnosis value of combined detection of serum mir-125b and alpha-fetoprotein for primary hepatocellular carcinoma |
| |
Affiliation: | ①.Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National"863" Plan Clinical Research Laboratory Tianjin 300060, China②.Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China |
| |
Abstract: | Objective To investigate the possibility of miR-125b in serum as a novel tumor marker for primary hepatocellular carcinoma (HCC) and the diagnosis value of combined detection of miR-125b and alpha-fetoprotein (AFP) for HCC. Methods We detected serum miR-125b expression of 65 cases of HCC patients and 30 cases of healthy controls by real-time quantitative PCR. Moreover, we analyzed the significance of miR-125b and explored the relationship between miR-125b and clinical pathological factors. Results The level of miRNA-125b was down regulated in serum of HCC patients compared with healthy controls which showed significant differences (P < 0.05). Furthermore, the expression of miRNA-125b has no distinct correlation with sex, age, HbsAg, AFP, ALT and α-GGT, which had no significant differences (P > 0.05). The expression level of miRNA-125b correlated the difference with liver Cirrhosis, tumor size and tumor node metastasis (TNM) stages, which were considered significant differences (P < 0.05). The receiver operating characteristic (ROC) curve analysis of serum miR-125b for the diagnosis of HCC yielded AUC of 0.917(95%CI: 0.851~0.960, P < 0.001)with 85.9% sensitivity and 93.5% specificity. The ROC curve analysis of combined miR-125b and AFP for HCC detection yielded AUC of 0.951(95%CI: 0.894~0.982, P < 0.001)with 92.9% sensitivity and 93.5% specificity. The ROC curve analysis of serum miR-125b as biomarkers for the group (AFP < 20 μg/L) of HCC yielded AUC of 0.889(95%CI: 0.776~0.957, P < 0.001)with 84.0% sensitivity and 87.1% specificity. Conclusions Serum miRNA-125b combined with AFP has considerable clinical value for the early diagnosis of primary HCC |
| |
Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|